Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.55 and traded as low as $0.49. Vaxart shares last traded at $0.70, with a volume of 28,790,756 shares changing hands.

Analyst Ratings Changes

VXRT has been the topic of a number of recent analyst reports. B. Riley dropped their target price on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. Wall Street Zen raised shares of Vaxart to a "hold" rating in a research report on Thursday, May 22nd.

Vaxart Stock Performance

The stock's 50-day moving average is $0.42 and its 200 day moving average is $0.55. The stock has a market capitalization of $160.27 million, a PE ratio of -1.71 and a beta of 1.25.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). The firm had revenue of $20.88 million for the quarter, compared to the consensus estimate of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. Analysts expect that Vaxart, Inc. will post -0.39 earnings per share for the current year.

Insider Activity at Vaxart

In other Vaxart news, insider Steven Lo purchased 100,000 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the purchase, the insider now directly owns 100,000 shares in the company, valued at approximately $49,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.90% of the company's stock.

Institutional Trading of Vaxart

A number of large investors have recently bought and sold shares of VXRT. Jones Financial Companies Lllp boosted its stake in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after purchasing an additional 478,111 shares during the period. Squarepoint Ops LLC boosted its stake in Vaxart by 95.0% during the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock worth $342,000 after purchasing an additional 251,789 shares during the period. Raymond James Financial Inc. acquired a new stake in Vaxart during the 4th quarter worth $129,000. Virtu Financial LLC acquired a new stake in Vaxart during the 1st quarter worth $56,000. Finally, Silverarc Capital Management LLC boosted its stake in Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock worth $714,000 after purchasing an additional 77,782 shares during the period. Institutional investors and hedge funds own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.